Cargando…

Repeatedly recurring pleomorphic adenoma: a therapeutic challenge

Pleomorphic adenoma (PA) is the most common tumour of the salivary glands, and can recur even after proper surgery. The extent and timing of surgery for recurrent tumours remains controversial, and multiple recurrences pose a special challenge. We evaluated all recurrent PAs (RPAs) treated at the He...

Descripción completa

Detalles Bibliográficos
Autores principales: ARO, K., VALLE, J., TARKKANEN, J., MÅKITIE, A., ATULA, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore Srl 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536033/
https://www.ncbi.nlm.nih.gov/pubmed/31131834
http://dx.doi.org/10.14639/0392-100X-2307
_version_ 1783421684070481920
author ARO, K.
VALLE, J.
TARKKANEN, J.
MÅKITIE, A.
ATULA, T.
author_facet ARO, K.
VALLE, J.
TARKKANEN, J.
MÅKITIE, A.
ATULA, T.
author_sort ARO, K.
collection PubMed
description Pleomorphic adenoma (PA) is the most common tumour of the salivary glands, and can recur even after proper surgery. The extent and timing of surgery for recurrent tumours remains controversial, and multiple recurrences pose a special challenge. We evaluated all recurrent PAs (RPAs) treated at the Helsinki University Hospital through 2004-2013 focusing on patients with multiple recurrences. Follow-up data were obtained until January 2018. Of the 47 patients, 70% were women and the median age was 33.5 years. Most of the RPAs were located in the parotid gland (87%), and six (13%) in the submandibular gland. One-third (17/47) of tumours had been primarily excised. This patient population experienced 75 recurrent events in total with two or more recurrences in 14 patients (30%). The time interval between recurrences shortened after each recurrent event and the tumour was more likely to be multifocal. At the end of the follow-up period, 15% had recurrent disease and malignant transformation had occurred in 6%. Treatment for PA and RPA is challenging and requires centralised management. Patients with RPA are often young and recurrences may cause lifelong morbidity, especially when the tumour recurs repeatedly. The utilisation and timing of postoperative radiotherapy needs to be discussed as well as the potential risk for malignant transformation in this patient population.
format Online
Article
Text
id pubmed-6536033
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Pacini Editore Srl
record_format MEDLINE/PubMed
spelling pubmed-65360332019-06-04 Repeatedly recurring pleomorphic adenoma: a therapeutic challenge ARO, K. VALLE, J. TARKKANEN, J. MÅKITIE, A. ATULA, T. Acta Otorhinolaryngol Ital Head and Neck Pleomorphic adenoma (PA) is the most common tumour of the salivary glands, and can recur even after proper surgery. The extent and timing of surgery for recurrent tumours remains controversial, and multiple recurrences pose a special challenge. We evaluated all recurrent PAs (RPAs) treated at the Helsinki University Hospital through 2004-2013 focusing on patients with multiple recurrences. Follow-up data were obtained until January 2018. Of the 47 patients, 70% were women and the median age was 33.5 years. Most of the RPAs were located in the parotid gland (87%), and six (13%) in the submandibular gland. One-third (17/47) of tumours had been primarily excised. This patient population experienced 75 recurrent events in total with two or more recurrences in 14 patients (30%). The time interval between recurrences shortened after each recurrent event and the tumour was more likely to be multifocal. At the end of the follow-up period, 15% had recurrent disease and malignant transformation had occurred in 6%. Treatment for PA and RPA is challenging and requires centralised management. Patients with RPA are often young and recurrences may cause lifelong morbidity, especially when the tumour recurs repeatedly. The utilisation and timing of postoperative radiotherapy needs to be discussed as well as the potential risk for malignant transformation in this patient population. Pacini Editore Srl 2019-06 /pmc/articles/PMC6536033/ /pubmed/31131834 http://dx.doi.org/10.14639/0392-100X-2307 Text en Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale, Rome, Italy http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), which permits for noncommercial use, distribution, and reproduction in any digital medium, provided the original work is properly cited and is not altered in any way. For details, please refer to https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Head and Neck
ARO, K.
VALLE, J.
TARKKANEN, J.
MÅKITIE, A.
ATULA, T.
Repeatedly recurring pleomorphic adenoma: a therapeutic challenge
title Repeatedly recurring pleomorphic adenoma: a therapeutic challenge
title_full Repeatedly recurring pleomorphic adenoma: a therapeutic challenge
title_fullStr Repeatedly recurring pleomorphic adenoma: a therapeutic challenge
title_full_unstemmed Repeatedly recurring pleomorphic adenoma: a therapeutic challenge
title_short Repeatedly recurring pleomorphic adenoma: a therapeutic challenge
title_sort repeatedly recurring pleomorphic adenoma: a therapeutic challenge
topic Head and Neck
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536033/
https://www.ncbi.nlm.nih.gov/pubmed/31131834
http://dx.doi.org/10.14639/0392-100X-2307
work_keys_str_mv AT arok repeatedlyrecurringpleomorphicadenomaatherapeuticchallenge
AT vallej repeatedlyrecurringpleomorphicadenomaatherapeuticchallenge
AT tarkkanenj repeatedlyrecurringpleomorphicadenomaatherapeuticchallenge
AT makitiea repeatedlyrecurringpleomorphicadenomaatherapeuticchallenge
AT atulat repeatedlyrecurringpleomorphicadenomaatherapeuticchallenge